A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Clinical trial NCT02944955 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT02944955
- Sponsor
- BioLite, Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2027-01-01
- Primary completion
- 2028-12-31
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.